Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Chinook Therapeutics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atrasentan Hydrochloride

            Therapeutic Area: Nephrology Product Name: ABT-627

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            Atrasentan is a potent, selective endothelin A receptor (ETA) antagonist that has been evaluated in diabetic kidney disease patients in studies that demonstrated clinically significant and sustained reductions in proteinuria, as well as reduced risk of kidney function decline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atrasentan Hydrochloride

            Therapeutic Area: Nephrology Product Name: ABT-627

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Aduro Biotech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger October 05, 2020

            Details:

            Chinook will focus on advancing its product candidates for kidney disease, including, Planned Phase 3 and Phase 2 trials of atrasentan, going Phase 1b and future clinical trials of BION-1301, planned Phase 1 trial of CHK-336 and additional R&D programs related to CKD.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atrasentan Hydrochloride

            Therapeutic Area: Nephrology Product Name: ABT-627

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: EcoR1 Capital

            Deal Size: $106.0 million Upfront Cash: Undisclosed

            Deal Type: Private Placement August 18, 2020

            Details:

            Net proceeds will support company's planned phase 2 and phase 3 trials of atrasentan, an investigational selective endothelin receptor antagonist, in development for the treatment of IgA nephropathy and other primary glomerular diseases including other clinical activities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atrasentan Hydrochloride

            Therapeutic Area: Nephrology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Aduro Biotech

            Deal Size: $225.0 million Upfront Cash: $200.0 million

            Deal Type: Merger June 02, 2020

            Details:

            Combined company will operate as chinook therapeutics and advance pipeline of clinical-stage programs in kidney diseases, led by Atrasentan and Bion-1301 in IGA nephropathy.